Roche bets on China with $468m Dx test facility in China
This article was originally published in Clinica
Executive Summary
Capitalizing on China’s increasing demand for lab testing services, Roche is planning to inject CHF450m ($468m) to build a new diagnostics plant in Suzhou Industry Park in Suzhou, Jiangsu province. The plant is Roche’s first in Asia and it will focus on producing immunochemistry and clinical chemistry tests and products that will meet the need for clinical lab testing as China continues to invest in health care.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.